Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4679245 | 0.85 | IGF1R (0.34) | IGF1R | |
| SCHEMBL4686151 | 0.84 | IGF1R (0.33) | IGF1RPOLBALDH1A1 | |
| SCHEMBL4683030 | 0.84 | IGF1R (0.33) | IGF1RPOLB | |
| SCHEMBL4679791 | 0.82 | BLM (0.37) | IGF1R | |
| SCHEMBL14066488 | 0.80 | PSEN1 (0.43) | IGF1R | |
| SCHEMBL3582885 | 0.78 | IGF1R (0.46) | IGF1RNOTUMPOLBJAK2ALDH1A1 | |
| SCHEMBL4680635 | 0.78 | IGF1R (0.32) | IGF1R | |
| SCHEMBL3591482 | 0.76 | IGF1R (0.40) | IGF1R | |
| SCHEMBL4679278 | 0.75 | IGF1R (0.37) | IGF1RNOTUMPOLBJAK2ALDH1A1 | |
| SCHEMBL4682699 | 0.73 | GAA (0.38) | POLBJAK2ALDH1A1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1437349-B9 | SUBSTITUTED ISOXAZOLES AND THE USE THEREOF AS ANTIBIOTICS | S A L V A T LAB SA (ES) | 2008-09-10 | — | — | EP | disclosed |
| EP-1437349-B1 | SUBSTITUTED ISOXAZOLES AND THE USE THEREOF AS ANTIBIOTICS | S A L V A T LAB SA (ES) | 2007-08-15 | — | — | EP | disclosed |
| US-20050014806-A1 | Substituted isoxazoles and their use as antibiotics | LABORATORIOS S.A.L.V.A.T., S.A. (ES) | 2005-01-20 | — | — | US | disclosed |
| EP-1437349-A1 | SUBSTITUTED ISOXAZOLES AND THE USE THEREOF AS ANTIBIOTICS | LABORATORIOS S.A.L.V.A.T., S.A. (ES) | 2004-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014806-A1 | Substituted isoxazoles and their use as antibiotics | XDH, SCO2, HAX1 | IGF1R 798/4885NOTUM 3353/4885POLB 1162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.